IFRX Earnings Date: Nov 3, 2026 (Estimated) — InflaRx N.V.
NASDAQ
Updated
When is IFRX's next earnings date?
InflaRx N.V. (IFRX) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.07 on revenue of $6,065.
How did IFRX do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), InflaRx N.V. posted EPS of -$0.10 versus the -$0.07 estimate, a miss of 25.0%. Revenue was $0 against a $5,996 estimate. The stock's 1-day post-earnings move was -2.8%.
How much does IFRX stock move after earnings?
IFRX beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.2% (up or down) in the day after earnings.
About InflaRx N.V.
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.07 | -0.10 | -25.00% | $0 | ❌ Miss | -2.82% | +13.56% | +25.99% |
| 2026-05-07 | Q1 2026 | -0.17 | -0.09 | +45.29% | $0 | ✅ Beat | +6.00% | +0.80% | -26.40% |
| 2026-03-19 | Q4 2025 | -0.18 | -0.17 | +5.56% | $-39,501 | ✅ Beat | +3.36% | +6.85% | +80.68% |
| 2025-11-10 | Q3 2025 | -0.19 | -0.21 | -10.53% | $27,862 | ❌ Miss | +28.46% | +9.76% | -13.82% |
| 2025-03-20 | Q4 2024 | -0.28 | -0.09 | +67.86% | $-451,463 | ✅ Beat | -1.56% | -3.13% | -17.19% |
| 2024-11-08 | Q3 2024 | -0.27 | -0.33 | -22.22% | $136,090 | ❌ Miss | +3.31% | +34.44% | +70.20% |
| 2024-05-08 | Q1 2024 | -0.24 | -0.18 | +25.00% | $39,138 | ✅ Beat | -3.23% | +15.32% | +29.84% |
| 2024-03-21 | Q4 2023 | -0.20 | -0.30 | -50.00% | $2,461 | ❌ Miss | -8.88% | -8.88% | -20.12% |
Showing last 8 quarters.
Revenue by segment & region
By region
FY2022 · $5.0M total · annual
| Segment | Share | Revenue | YoY |
|---|---|---|---|
| GERMANY | 98.0% | $4.9M | — |
| UNITED STATES | 2.0% | $100K | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.